Experts shared the key data that stood out in hematologic oncology at the 2026 ASCO Annual Meeting.
|Videos|June 5, 2011
Dr. Tsimberidou Discusses Improving Care
Author(s)Apostolia Tsimberidou, MD, PhD
Apostolia M. Tsimberidou, MD, PhD, from MD Anderson Cancer Center discusses improving cancer care.
Advertisement
Lead author Apostolia M. Tsimberidou, MD, PhD, of the University of Texas MD Anderson Cancer Center, discusses how the personalized medicine program phase I trial looking at tumor molecular analysis and the use of targeted matched therapy improves the outcomes of affected patients, and cancer care in general.
Advertisement
Related to this article
The TRIPP-FFX trial met its primary end points of local disease control and safety with P-32 microparticles plus FOLFIRINOX pancreatic adenocarcinoma.
Readouts across LBCL, relapsed/refractory myeloma, and CALR-mutated myelofibrosis anchored the hematology data presented at EHA 2026.
Phase 1/2 data from 2 trials showed high ORRs with zoldonrasib-based regimens in first-line and previously treated RAS G12D metastatic pancreatic ductal adenocarcinoma.
Hematologic oncology experts outline the top data and themes to emerge from the 2026 EHA Congress
In EMERALD-3, STRIDE with or without lenvatinib plus TACE improved PFS, ORR, and DOR vs TACE alone by RECIST 1.1 and mRECIST criteria in HCC.
Updated data from the GALAXY study showed an association between postsurgical MRD positivity per Signatera and OS benefit with adjuvant chemotherapy.
First-line domvanalimab plus zimberelimab and chemotherapy did not improve OS vs nivolumab plus chemotherapy in HER2-negative gastroesophageal cancer.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC
2
PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings
3
META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL
4
CD33-Directed CAR T-Cell Therapies Elicit Complete Remissions in Relapsed/Refractory AML
5